Martis Capital, a middle-market private equity firm focused exclusively on the healthcare industry, is pleased to kick off 2024 with two investment team promotions. Aseem Nambiar has been promoted from Director to Principal, and David Zhang from Vice President to Director.
Based in San Francisco, CA, Aseem joined Martis in 2019 and helps lead the firm’s investments in DCN Dx, Lighthouse Lab Services and WellHaven PetHealth. Prior to Martis, he held an operating role at DaVita, following his time at Waud Capital and UBS. Aseem received a Bachelor of Science in Quantitative Economics from Tufts University and an MBA from the University of Pennsylvania.
Based in San Francisco, CA, David joined Martis in 2020 and helps lead the firm’s investments in Alcanza Clinical Research, Lighthouse Lab Services and Rise Health. He started his career at Barclays, then focused on middle-market buyout investing at Welsh, Carson, Anderson & Stowe and Calera Capital. David received a Bachelor in Business Administration from the Stephen M. Ross School of Business at the University of Michigan.
“With the final closing of Fund IV and active deal activity across new platforms and add-ons, the past twelve months have marked a period of continued strong growth for Martis Capital. As we head into the new year, we’re thrilled to recognize Aseem’s and David’s contributions to the firm, as well as their professional growth and achievement,” said Founding & Managing Partner, Barry Uphoff.
About Martis Capital
Based in Washington, DC and San Francisco, Martis Capital is a founder-friendly capital partner for growth-oriented healthcare companies. Since 2011, Martis Capital has raised more than $2.2 billion from a global base of institutional clients to invest in the middle-market North American healthcare sector. For more information, visit www.martiscapital.com.